Radiopharmaceuticals have lit up – possibly even sparking more interest than antibody-drug conjugates, which have seen significant M&A activity in recent months.
Strong data from Novartis’ oncology treatments, Lutathera and Pluvicto, coupled with developers’ pursuit of an alternative modality that offers “pan-cancer” potential, have driven multibillion-dollar acquisitions in the past six months, a $350m IPO, and a surge in venture capital investments. Developers large and small are scurrying to buy or build better versions of Novartis’ duo and test them across a wider range of cancers.
In this eBook, we explore the latest science, dealmaking, and commercial opportunities in the radiopharmaceutical landscape, highlighting some of its most intriguing players.
Highlights:
- Radiopharmaceuticals: What’s the appeal?
- The next wave: Ones to watch
- Alpha radiation: the next frontier?
- Small molecules: What’s their role?
- Key players in the field: How do they stack up?
